Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04479267
Title Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Barbara Ann Karmanos Cancer Institute

diffuse large B-cell lymphoma


Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisolone + Rituximab

Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab

Cyclophosphamide + Doxorubicin + Methylprednisolone + Polatuzumab vedotin-piiq + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.